How is IGF-1 LR3 dosed, and how does a dose read on a syringe?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds IGF-1 LR3 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
A search located no label for IGF-1 LR3, and a review lists no peer-reviewed human studies; the review reports bodybuilding-forum dosing of 20-40 µg per day, once daily, which it says is not evidence-based treatment.1
The guide's example
40 mcg of IGF-1 LR3 from a 1 mg vial mixed with 1 mL is 4 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 1 mg | 1 mg/mL: 20 mcg is 2 units, 40 mcg is 4 units | 0.5 mg/mL: 20 mcg is 4 units, 40 mcg is 8 units |
Mixing a 1 mg vial and reading units
GenScript lists its research-use LR3-IGF-I in 100 µg and 1 mg sizes, reconstituted in 10 mM HCl up to 1 mg/mL.2 It labels the powder for laboratory use only and forbids direct human use, including injection.2 A search located no label or regulator document for IGF-1 LR3, and the search located no liquid volume for the vial.
As arithmetic only, 40 µg, the top of the forum range the review reports, from a 1 mg vial mixed with 1 mL of liquid is 0.04 mL, or 4 units on a U-100 syringe.1
40 mcg of IGF-1 LR3 from a 1 mg vial mixed with 1 mL is 4 units on a U-100 syringe.
Dose and schedule
The review lists IGF-1 LR3 as having no peer-reviewed human studies, so no trial arm has a dose to report.1 Its dosing table gives one IGF-1 LR3 entry, from bodybuilding-related forums: 20-40 µg per day by SC or IM injection, once daily, ideally after a workout.1 The same forums describe a cycle of 4-6 weeks on followed by an equal period off.1 The review calls its dosing table anthropological data, not evidence-based treatment.1
Storage
The Increlex label gives 2° to 8°C for unopened vials, and 30 days at 2° to 8°C after first entry, not frozen.3 GenScript says its reconstituted research product is stable for 1 week at 4°C or 3 months at -20°C.2 The search located no storage data for IGF-1 LR3 made for human use; the figures above come from a research-reagent maker and from the label of a different product.
Frequently asked questions
What side effects are reported for IGF-1 LR3?
The review says reported off-label adverse effects frequently centre on insulin-mimetic activity, such as symptoms suggestive of hypoglycaemia, and that many such reports come from non-clinical sources and call for caution.1 The Increlex label, for mecasermin rather than IGF-1 LR3, warns that severe hypoglycaemia leading to seizures has been observed with Increlex treatment.3
Is IGF-1 LR3 approved for bodybuilding?
The review says the compounds it covers have no regulatory approval for physique or performance use.1
- IGF-1 LR3 calculatorThe mixing sum for other volumes.
- Mixing guideThe general steps.
- IGF-1 LR3Half-life, animal studies and WADA status.
- Growth hormone peptidesThe class overview.
- Tesamorelin dosageLabel dose and schedule.
- CJC-1295 and ipamorelin dosageMixing and units.
- HGH dosage in IUGrowth hormone doses.
References
- Frontiers in Endocrinology. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
- GenScript. LR3-IGF-I (Receptor Grade), Human - GenScript. genscript.com
- DailyMed (Eton Pharmaceuticals). These highlights do not include all the information needed to use INCRELEX ® safely and effectively. See full prescribing information for INCRELEX ® . INCRELEX ® (mecasermin) injection, for subcutaneous use Initial U.S. Approval: 2005. 2026. dailymed.nlm.nih.gov